Amarin Is Prepared To Be ‘Aggressive’ With Vascepa Authorized Generic
Originator Restructures And Names New CEO Following Icosapent Ethyl Competition
Amarin’s management has suggested that it would be prepared to compete “very aggressively” with a US authorized generic version of its Vascepa if and when it decides to launch. The comments came as the originator named a new CEO and restructured in the wake of increasing generic competition.
